Cyamemazine ( Tercian), also known as cyamepromazine, is a typical antipsychotic drug of the phenothiazine class which was introduced by Theraplix in France in 1972 and later in Portugal as well.    It is used for the treatment of  schizophrenia and, especially, for psychosis-associated anxiety, due to its unique anxiolytic efficacy.  
Cyamemazine differs from other phenothiazine neuroleptics in that aside from the usual profile of
dopamine, α, 1-adrenergic H, and 1 mACh receptor antagonism, it additionally produces potent blockade of several  serotonin receptors, including 5-HT, 2A 5-HT, and 2C 5-HT. 7    These actions have been implicated in cyamemazine's anxiolytic effects (5-HT  2C) and lack of extrapyramidal side effects (5-HT 2A),  and despite being classified as a typical, it actually behaves like an  atypical antipsychotic. 
See also [ edit ]
References [ edit ]
^ . Index nominum, international drug ... - Google Books
^ David J. Triggle (1996). . Boca Raton: Chapman & Hall/CRC. p. 534. Dictionary of Pharmacological Agents ISBN 0-412-46630-9.
^ . Pharmaceutical manufacturing ... - Google Books
^ Bret P, Bret MC, Queuille E (April 2009). "[Prescribing patterns of antipsychotics in 13 French psychiatric hospitals]". L'Encéphale (in French). 35 (2): 129–38. doi: 10.1016/j.encep.2008.03.007. PMID 19393381.
^ "Stahl's Essential Psychopharmacology - Cambridge University Press".
^ Bourin M, Nic Dhonnchadha BA, Claude Colombel M, Dib M, Hascoët M (September 2001). "Cyamemazine as an anxiolytic drug on the elevated plus maze and light/dark paradigm in mice". Behavioural Brain Research. 124 (1): 87–95. doi: 10.1016/S0166-4328(01)00238-8. PMID 11423169.
^ a b c Hameg A, Bayle F, Nuss P, Dupuis P, Garay RP, Dib M (February 2003). "Affinity of cyamemazine, an anxiolytic antipsychotic drug, for human recombinant dopamine vs. serotonin receptor subtypes". . Biochemical Pharmacology 65 (3): 435–40. doi: 10.1016/S0006-2952(02)01515-0. PMID 12527336.
^ a b Alvarez-Guerra M, d'Alché-Birée F, Wolf WA, Vargas F, Dib M, Garay RP (January 2000). "5-HT3- and 5-HT2C-antagonist properties of cyamemazine: significance for its clinical anxiolytic activity". Psychopharmacology. 147 (4): 412–7. doi: 10.1007/s002130050010. PMID 10672635.
^ Alvarez-Guerra M, Hameg A, Bayle F, Dib M, Garay RP (November 2002). "5-HT2A receptor antagonist properties of cyamemazine in rat and guinea pig smooth muscle". European Journal of Pharmacology. 454 (2-3): 235–9. doi: 10.1016/S0014-2999(02)02489-5. PMID 12421652.
^ Benyamina A, Arbus C, Nuss P, Garay RP, Neliat G, Hameg A (January 2008). "Affinity of cyamemazine metabolites for serotonin, histamine and dopamine receptor subtypes". European Journal of Pharmacology. 578 (2-3): 142–7. doi: 10.1016/j.ejphar.2007.09.025. PMID 17936750.
^ Peinado J, Hameg A, Garay RP, Bayle F, Nuss P, Dib M (February 2003). "Reduction of extracellular dopamine and metabolite concentrations in rat striatum by low doses of acute cyamemazine". Naunyn-Schmiedeberg's Archives of Pharmacology. 367 (2): 134–9. doi: 10.1007/s00210-002-0665-4. PMID 12595954.